Nyxoah SA has released its preliminary financial results for the third quarter of 2026, revealing a significant 29% increase in U.S. net revenue. This growth comes as the company adjusts its full-year revenue guidance, now expecting between €33 million and €35 million. The announcement underscores Nyxoah's expanding role in the medical technology sector, particularly in the treatment of obstructive sleep apnea (OSA).

Background

Nyxoah SA, a medical technology company, specializes in developing innovative solutions for treating OSA through neuromodulation. The company operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. Nyxoah is publicly traded on the Nasdaq under the ticker symbol NYXH and has been active in the market since its IPOs on Euronext Brussels in September 2020 and on Nasdaq in July 2021.

What the Filing Says

According to the SEC filing dated October 20, 2026, Nyxoah reported that its global net revenue for Q3 2026 is expected to be approximately €9.2 million, reflecting a 19% sequential growth over the previous quarter. Notably, U.S. net revenue is projected to be around €6.7 million, marking a 29% increase from Q2 2026. The company has also submitted a PMA supplement to the FDA to expand its Genio system's U.S. indication to include Complete Concentric Collapse patients.

Impact

This update may impact various stakeholders, including investors, healthcare providers, and patients suffering from OSA. The growth in revenue indicates a rising demand for Nyxoah's products, particularly the Genio system, which is designed to provide alternative treatment options for patients. Additionally, the company's ability to attract new surgeons and activate accounts suggests a strengthening market presence.

What's Next

The filing does not specify what happens next, but Nyxoah is expected to continue its efforts in expanding its market reach and enhancing its product offerings. The company remains optimistic about its growth trajectory and the increasing acceptance of its technology among healthcare professionals.